Status:
COMPLETED
Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
Pfizer
Planned Parenthood Federation of America
Conditions:
Fertility
Eligibility:
FEMALE
18-50 years
Brief Summary
The purpose of this study is to assess continuation rates and patient satisfaction with self administration subcutaneous depot medroxyprogesterone acetate.
Detailed Description
This observational study will include new or current Depo Provera users who express interest in attempting subcutaneous self administration of depot medroxyprogesterone acetate. Candidates will be tau...
Eligibility Criteria
Inclusion
- Women 18 years or older
- Can understand written and spoken English
- Current or past user of DMPA or desires initiation of DMPA for contraception
- Provider has approved DMPA use in this woman
- Willing to consider/attempt DMPA self-injection.
- Willing to receive phone calls/letter for follow up
- Willing to return letters for follow up
Exclusion
- Has contraindications to DMPA use:
- Vaginal bleeding of unknown etiology
- Medication use for Cushing's syndrome
- Currently pregnant
- Blood pressure \>160/100
- Intolerance to the idea of irregular or absent menses
Key Trial Info
Start Date :
May 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00770887
Start Date
May 1 2010
End Date
June 1 2011
Last Update
August 11 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Planned Parenthood of Southwest and Central Florida
Fort Myers, Florida, United States, 33919
2
Planned Parenthood of Southwest and Central Florida
Tampa, Florida, United States, 33617